Bone Biologics Provides Mid-Year Shareholder Update on 2026 Progress

Bone Biologics issued a shareholder update highlighting progress in clinical development, manufacturing readiness, and capital position. The company completed a $3 million financing to support NB1's first-in-human study through Q2 2027.

By BONE BIOLOGICS CORPORATION · GlobeNewsWire · July 23, 2026, 12:00 UTC

Bone Biologics Provides Mid-Year Shareholder Update on 2026 Progress

Topics: capital raise clinical development manufacturing readiness

Read the full article at GlobeNewsWire

More World news

BlueMatrix Completes Acquisition of AI-Enabled Research Platform Aiera PR Newswire · November 12, 2026, 15:15 UTC
U.S. Lawmakers Respond to Jensen Huang's Resignation as Nvidia CEO Seeking Alpha · November 12, 2026, 15:12 UTC
OpenAI Secures $15 Billion in New Funding at $1.25 Trillion Valuation Seeking Alpha · November 12, 2026, 15:13 UTC
Digi International Shares Fall 18% Following Fiscal Q4 Earnings Release Seeking Alpha · November 12, 2026, 15:13 UTC
Pomerantz Law Firm Investigates Artiva Biotherapeutics Following Program Discontinuation and Fatal Safety Events PR Newswire · November 12, 2026, 15:15 UTC
Major Corporate Earnings Scheduled for Release After Thursday Market Close Seeking Alpha · November 12, 2026, 15:00 UTC
U.S. Existing Home Sales Decline More Than Expected in October Seeking Alpha · November 12, 2026, 15:03 UTC
Ascendis Pharma Reports Strong Q3 2026 Results Driven by Yorvipath Growth Motley Fool · November 12, 2026, 15:09 UTC
Pomerantz Law Firm Investigates Omeros Corporation Following Regulatory Setbacks PR Newswire · November 12, 2026, 15:10 UTC
Pomerantz Law Firm Investigates Innodata Inc. Following Mass Layoffs and Stock Price Drop PR Newswire · November 12, 2026, 15:10 UTC